Koers Biodexa Pharmaceuticals Plc London S.E.
Aandelen
BDRX
GB00BNGF1L75
Biotechnologie & Medisch Onderzoek
Omzet 2023 * | 298K 371K 348K | Omzet 2024 * | - | Marktkapitalisatie | 1,79 mln. 2,23 mln. 2,09 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | 6,01 x |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-
| K/w-verhouding 2024 * |
-
| Werknemers | 27 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 57,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vincent Holmes
COO | Chief Operating Officer | - | - |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29-10-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,39% | 102 mld. | |
+2,61% | 96,09 mld. | |
-1,02% | 22,05 mld. | |
-18,14% | 20,81 mld. | |
-6,87% | 19,06 mld. | |
-40,70% | 16,05 mld. | |
-26,89% | 14,01 mld. | |
+1,12% | 13,38 mld. | |
+22,25% | 11,01 mld. |